Figure 6
Superior therapeutic efficacy of M-MSCs compared to BM-MSCs. (a) Representative awake cystometry results at 1 week after injection of M-MSCs or BM-MSCs at the indicated dosage (K = a thousand) into the bladder of HCl-IC rats. (b) The micturition pressure (MP), basal bladder pressure (BP), bladder capacity (BC), micturition volume (MV), residual volume (RV), and micturition interval (MI) were quantified from the voiding pattern analysis. (c) Quantification of non-voiding contraction (NVC) in HCl-IC animals transplanted with the indicated number of M-MSCs or BM-MSCs (n = 8). All data are presented as the mean ± SEM from 8 independent animals per group (*p < 0.05, **p < 0.01, ***p < 0.001 compared to the HCl-IC group; #p < 0.05, ##p < 0.001, ###p < 0.001 compared to M-MSC (250 K) group by one-way analysis of variance with Bonferroni post-test). (d) The time course of viability of transplanted M-MSCs or BM-MSCs (2.0 × 105) in cyclophosphamide (CYP)-induced IC/BPS mice. Relative bioluminescent signals for the indicated day after transplantation (DAT) relative to 0 DAT are presented as the mean ± SEM (n = 5; ***p < 0.001 compared to the BM-MSC group). The representative images were obtained at 15 minutes after intraperitoneal injection of 150 μg/ml coelenterazine (200 μL), a substrates for Renilla luciferase. The scale bars for optical image density range at 0 and other day points were presented at left and right sides of image, respectively.
